HealthDay News — A highly personalized therapy targeting multiple tumor antigens shows promise for metastatic breast cancer, according to a research letter published online June 4 in Nature Medicine.

Nikolaos Zacharakis, PhD, from the National Institutes of Health in Bethesda, Maryland, and colleagues present the case of a 49-year-old woman with chemorefractory hormone receptor-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes that were reactive against mutation versions of 4 proteins (SLC3A2, KIAA0368, CADPS2, and CTSB). 

Related Articles

The researchers found that adoptive transfer of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer, with the target tumor burden reduced by 51% at the first evaluable time points 6 weeks after cell transfer. At 22 months after cell transfer, all target and nontarget lesions had resolved radiologically.

“Metastatic breast cancer can be a heterogeneous disease, and this patient demonstrated that a personalized therapy tailored to target the unique somatic mutations presented by the autologous tumor of the affected individual can mediate complete durable cancer regression,” the authors write.

Abstract/Full Text (subscription or payment may be required)